Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial

Brian G. Feagan*, Bruce E. Sands, William J. Sandborn, Matthew Germinaro, Marion Vetter, Jie Shao, Shihong Sheng, Jewel Johanns, Julián Panés, VEGA Study Group

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

139 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial'. Together they form a unique fingerprint.

Medicine & Life Sciences